Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
Tongji Hospital, Wuhan, Hubei, China
Anhui Provincial People's Hospital, Hefei, Anhui, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Tumor Hospital of Jiangxi Province, Nanchang, Jiangxi, China
People's Hospital of Ganzhou, Ganzhou, Jiangxi, China
the First Affiliated Hospital of Gannan Medical College, Gannan Medical College, Ganzhou, Jiangxi, China
Evangelismos General Hospital, Athens, Greece
the Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi, China
Zhejiang Cancer Hospital, Hanzhou, China
Centre Hospitalier Sud Francilien, Corbeil-essonnes Cedex, France
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Department of Anesthesiology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.